ADC Therapeutics Quote - ADCT

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.98

Bid

Offer

Volume

508

0.00 Day's Range 0.00

0.684 52 Week Range 6.04

Market Cap

191.445M

Previous Close

1.98

Open

Last Trade

1.98

Last Trade Time

00:38:50

Financial Volume

VWAP

Average Volume (3m)

377,803

Shares Outstanding

96,689,617

Dividend Yield

PE Ratio

-0.82

Earnings Per Share (EPS)

-2.43

Revenue

69.56M

Net Profit

-234.53M

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more

Sector

Drugs And Proprietary-whsl

Industry

Drugs And Proprietary-whsl

Website

www.adctherapeutics.com

Headquarters

Lausanne, Che

Founded

ADC Therapeutics SA is listed in the Drugs And Proprietary-whsl sector of the New York Stock Exchange with ticker ADCT. The last closing price for ADC Therapeutics was US$1.98. Over the last year, ADC Therapeutics shares have traded in a share price range of US$ 0.684 to US$ 6.04.

ADC Therapeutics currently has 96,689,617 shares in issue. The market capitalisation of ADC Therapeutics is US$191.45 million. ADC Therapeutics has a price to earnings ratio (PE ratio) of -0.82.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update PR Newswire LAUSANNE, Switzerland, Nov. 7, 2024 LOTIS-5 full enrollment and LOTIS-7...

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting PR Newswire LAUSANNE, Switzerland, Nov. 5, 2024 Oral presentation of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.84	-29.7872340426	2.82	2.87	1.885	492994	2.23832581	CS
4	-1.01	-33.779264214	2.99	3.3	1.885	431506	2.76163612	CS
12	-1	-33.5570469799	2.98	3.45	1.885	377803	2.93821082	CS
26	-2.12	-51.7073170732	4.1	4.17	1.885	472882	3.14820895	CS
52	1.28	182.857142857	0.7	6.04	0.684	608428	3.22586574	CS
156	-20.85	-91.3272010512	22.83	23.2832	0.359908	470507	4.03393337	CS
260	-28.02	-93.4	30	56.5899	0.359908	397269	9.64404765	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PSBDPalmer Square Capital BDC Inc	US$ 22.99 (44.32%)	15
ACRACRES Commercial Realty Corporation	US$ 23.99 (43.31%)	291
MEGMontrose Environmental Group Inc	US$ 25.45 (41.86%)	40
SNDASonida Senior Living	US$ 33.00 (38.83%)	23
SDHYPGIM Short Duration High Yield Opportunities Fund	US$ 21.95 (32.63%)	3
BTTBlackRock Municipal 2030 Target Term Trust	US$ 11.01 (-47.67%)	2
AVNSAvanos Medical Inc	US$ 11.01 (-38.39%)	118
SMPStandard Motor Products Inc	US$ 20.00 (-36.67%)	103
CBANColony Bankcorp Inc	US$ 11.12 (-34.47%)	6
SDHCSmith Douglas Homes Corp	US$ 21.00 (-32.78%)	221
SNOWSnowflake Inc	US$ 160.5383 (24.33%)	1.72M
PLTRPalantir Technologies Inc	US$ 61.9201 (-0.32%)	1.42M
NIONIO Inc	US$ 4.60 (-1.08%)	1.29M
KMIKinder Morgan Inc	US$ 28.16 (0.57%)	890.52k
TSNTyson Foods	US$ 62.81 (-0.70%)	876.33k